Research from the
St. Jude LIFE study found childhood osteosarcoma survivors have a higher risk for learning and memory problems.
Enzyme linked to neurodegenerative disorders may play a reversible role in enhancing the aggressiveness of sarcoma tumors.
Drug discovery project raises hopes for drugs targeting intrinsically disordered proteins, which are associated with range of human diseases.
Landmark study shows almost one in 10 children with cancer were born with an increased genetic risk for the disease.
Evidence suggests that variations in the ETV6 gene may play a significant role in inherited predisposition to most common childhood cancer — ALL.
Online cognitive training offers expanded access to effective method of improving working memory and easing late effects of cancer treatment.
St. Jude researchers discovered that bile acid buildup in the liver during pregnancy can cause intrahepatic cholestasis of pregnancy.
Researchers identify mechanism that plays key role in cellular organization and offers insight into treatment of degenerative diseases like ALS.
Researchers reveal how alterations in IKZF1 gene drive an aggressive leukemia and a strategy to enhance the effectiveness of existing therapies
St. Jude scientists lead effort that uncovers the mechanism involved in the most common genetic cause of two neurodegenerative disorders.
St. Jude scientists have discovered another way the tumor suppressor protein p53 earns its title as guardian of the genome.
A new era of personalized medicine has begun for some patients with the brain tumor medulloblastoma.
St. Jude researchers have discovered a potential new method for determining whether masses in the chest cavity are a fungal infection or a tumor without performing a biopsy.
St. Jude scientists use new methods to show that one type of stem cell is superior to another for treating retinal degeneration in research that could significantly advance such treatments
St. Jude discovery lays the foundation for developing new, much needed chemotherapy agents and finds evidence that anti-cholesterol drugs called statins slow growth of ependymoma tumor cells.
Research led by
St. Jude found that deaths from late effects of childhood cancer treatment have declined in recent decades and survivors are living longer.
J. Paul Taylor, M.D., Ph.D., of
St. Jude Children's Research Hospital, has been recognized as one of the nation's leading biomedical researchers by the Howard Hughes Medical Institute.
St. Jude scientists show that mutations in the DDX3X gene lead to different molecular defects, findings which will aiding in developing more individualized therapy of medulloblastoma.
Researchers led by
St. Jude scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases.
St. Jude scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing.
Researchers have identified a protein that offers a new focus for developing targeted therapies to tame the severe inflammation associated with multiple sclerosis, colitis and other autoimmune disorders.
Clinical fellow Jason Schwartz, M.D., Ph.D., Oncology, a former
St. Jude patient, discusses what it’s like to experience his first Doctors’ Day.
Measuring treatment response proves to be a powerful tool for guiding leukemia therapy.
St. Jude scientists identify key molecular events in pediatric adrenocortical tumors. The findings could help clinicians identify most malignant subtypes and lead to better treatment.
Researchers with the Pediatric Cancer Genome Project have completed the most comprehensive DNA analysis yet of the most common form of ALL in infants.
The Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy.
Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug.
Researchers like to ask basic questions about how the world and the things in it work. Answers to those questions can advance science and protect health.
St. Jude researchers have reported more evidence that many childhood cancer survivors need their pituitary function checked annually.
Cisplatin is one of the most widely used anti-cancer drugs. Many patients treated with the drug also have serious side effects like hearing loss.
St. Jude scientists have linked inherited variations in a second gene to reduced tolerance of a key cancer drug. Findings will aid efforts to improve chemotherapy safety and effectiveness.
St. Jude have discovered that a protein widely known for preventing tumors also helps regulatory T cells do their job.